NASDAQ: AHCO · Medical Devices
AdaptHealth (AHCO) fair value and price range
As of 14 Nov 2026, Faircurve's model values AdaptHealth (AHCO) at $7.47 a share. The stock last closed at $7.53, which puts the model's fair value 0.8% below the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 17 Nov 2026. AdaptHealth Corp.
The report adds the live price, the price chart, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $7.18 to $7.47 (+4.0%). The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move.
What the model makes of itThe price of $7.53 is 0.8% above it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextNext report on 2 Mar 2027. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give AHCO?
The calibrated range for AHCO over 63 trading days is $5.97 to $8.87. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 13,250 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $3.48 to $11.81. In 49% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
AdaptHealth Corp. is a healthcare company in the medical devices sector. Alongside its network of subsidiaries, it delivers a comprehensive range of home medical equipment (HME), supplies, and associated services across the United States.
Faircurve's model put the fair value of AdaptHealth Corp. at $7.47 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $7.18, so the fair value moved +4.0%. In the model's own words, the stock's own trading multiple rose, and the fair value follows it in part: most of the move. The calibrated range over 63 trading days is $5.97 to $8.87, built from the fair value because there is no live options data for the stock. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence behind this valuation as low.
AdaptHealth's overall quality score is 37 out of 100, measured against comparable companies. The factors that stand out most are growth quality, at 15, against a peer median revenue growth of 14.2%, and profitability, at 30, with ROIC of -6.6% against a peer median of -4.2%. The balance sheet factor scores 0. The model compares the company with Integra LifeSciences Holdings Corporation (IART), Artivion, Inc. (AORT), Cytek Biosciences, Inc. (CTKB), Enovis Corporation (ENOV) and UFP Technologies, Inc. (UFPT).
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does AHCO report earnings, and how has the stock reacted?
AdaptHealth's next earnings report is scheduled for 2 Mar 2027. Companies can move their dates.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across AHCO's last 8 reports, ignoring direction, was 13.1%.
How does AHCO score on business quality?
AdaptHealth's overall quality score is 37 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 30 | -6.6%ROIC | -4.2% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 100 | ||
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 15 | -0.5%Revenue growth, trailing | 14.2% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 27 | 0.0%Net buybacks / market value | 1.9% |
| Balance sheetNet debt to EBITDA and interest coverage. | 0 | 24.40xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 22 | 8.6 ptsEBITDA margin downside volatility, 5y | 3.9 pts |
How does AHCO compare with similar companies?
The companies in medical devices closest to AdaptHealth in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| IART Integra LifeSciences Holdings Corporation | $13.55 | $16.00 | +18.1% | Undervalued |
| AORT Artivion, Inc. | $18.27 | $20.28 | +11.0% | Fairly valued |
| TNDM Tandem Diabetes Care, Inc. | $17.06 | $21.89 | +28.3% | Low evidence grade |
| CTKB Cytek Biosciences, Inc. | $5.70 | $6.03 | +5.8% | Fairly valued |
| CNMD CONMED Corporation | $48.39 | $50.43 | +4.2% | Low evidence grade |
| ENOV Enovis Corporation | $27.22 | $32.77 | +20.4% | Undervalued |
| INSP Inspire Medical Systems, Inc. | $59.41 | $61.27 | +3.1% | Low evidence grade |
| UFPT UFP Technologies, Inc. | $297.49 | $266.65 | -10.4% | Fairly valued |
What the comparable companies' multiples alone would give for AHCO, the peer-implied price, is $5.81 a share on this run. The fair value weighs that against the company's own multiple.
AdaptHealth at a glance
AdaptHealth Corp., alongside its network of subsidiaries, delivers a comprehensive range of home medical equipment (HME), supplies, and associated services across the United States.
- Market value
- $1.0B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $3.0B
- Consensus revenue growth, next fiscal year
- -10.4%
- Analysts with estimates
- 2
- Beta to the US market
- 0.11
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices AdaptHealth on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for AHCO was $7.18. As of 14 Nov 2026 it is $7.47, a change of +4.0%. The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about AdaptHealth's valuation
Is AdaptHealth stock undervalued or overvalued?
Faircurve's model puts AHCO's fair value at $7.47 a share against a last close of $7.53, as of 14 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is AHCO's fair value?
$7.47 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $3.48 to $11.81.
What price range does the model give AHCO?
$5.97 to $8.87 over 63 trading days. Ranges built this way held the price 60% of the time across 13,250 past valuations, refreshed 14 Nov 2026.
When does AdaptHealth report earnings next?
The next report is scheduled for 2 Mar 2027. Companies can move their dates.
How much has AHCO moved on past earnings reports?
Across its last 8 reports the median two session move was 13.1%, ignoring direction. The largest was -40.0% around the report of 4 Aug 2026.
How confident is the model in this valuation?
The model's evidence grade for AHCO is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on AHCO
The model holds no idea open on AHCO today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on AHCO with their outcomes. A free account is enough.